Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-09-18
2007-09-18
Kifle, Bruck (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C540S456000
Reexamination Certificate
active
10930487
ABSTRACT:
The present invention provides an amorphous form of rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid. This invention also provides processes for preparing the amorphous form and pharmaceutical compositions including the amorphous form.
REFERENCES:
patent: 5362718 (1994-11-01), Skotnicki et al.
patent: 5989591 (1999-11-01), Nagi
patent: 6004973 (1999-12-01), Guitard et al.
patent: 6197781 (2001-03-01), Guitard et al.
patent: 2003/0008835 (2003-01-01), Guitard et al.
patent: 2004/0077677 (2004-04-01), Ashraf et al.
patent: WO-01/23395 (2001-04-01), None
patent: WO-2004/026280 (2004-04-01), None
Lee et al., Particle Size Reduction in “Water Insoluble Drug Formulation”, (R. Liu, Ed.) Interpharm Press Co., Denver, CO 392-473, 2000.
Vippagunta et al., “Crystalline Solids”, Adv. Drug Del. Rev., May 16, 2001 48(1):3-26.
Atkins, P., Physical Chemistry, 2nd Edition (1986).
Farmacia Hospitalaria, pp. 1590-1592 (2004).
Monographs on Chemical Derivatives, Stearic Acid (2004).
Ashraf Muhammad
Benjamin Eric J.
Jain Ashwinkumar
Howson & Howson LLP
Kifle Bruck
Milowsky Arnold S.
Wyeth
LandOfFree
Amorphous rapamycin 42-ester with... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Amorphous rapamycin 42-ester with..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Amorphous rapamycin 42-ester with... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3757024